Remote monitoring of side effects from melanoma treatment
Part of Cancer, Skin clinical trials.
This study tests a smartphone app called Vigilant that helps monitor side effects from a melanoma treatment (ipilimumab and nivolumab). You may be able to join if you are about to start this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have skin cancer or melanoma.
- You are about to start treatment with a combination of ipilimumab and nivolumab.
- You are willing to use a smartphone app for monitoring.
- You do not have another condition or reason that would prevent participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using home digital monitoring (telemonitoring) can help people with melanoma, lung, or kidney (renal) cancer manage side effects while on immunotherapy. It may help catch side effects earlier and support you during treatment with nivolumab plus ipilimumab or nivolumab alone.
This trial tests a program that helps melanoma patients starting immunotherapy track their side effects and get faster access to specialists. The goal is to improve symptom management.
This study is looking at whether a special PET scan (FDG PET/CT) and a blood test that measures ctDNA (cancer DNA in the blood) can help predict how well immune checkpoint inhibitors work in people with advanced melanoma. If you are planning to get treatment with immunotherapy drugs like ipilimumab, nivolumab, or pembrolizumab, you may be able to join.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.